BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement

BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement

Story continues below

On March 26, 2018, to a Subscription Agreement, Orthofix Holdings, Inc. purchased 250,000 restricted shares (the “Shares”) of the Company’s Common Stock at $2.00 per share. The Shares are subject to demand registration rights as described in the Subscription Agreement.

The Form of the Subscription Agreement is attached as Exhibit 10.1 to this Report, and the summary description of the terms of the Subscription Agreement contained herein is qualified in its entirety by reference to Exhibit 10.1.

Item 3.02 Unregistered Sales of Equity Securities

The discussion in Item 1.01 is hereby incorporated by reference.

The Shares (the “Securities”) will be issued in reliance of Section 4(a)(2) of the Securities Act of 1933, as amended. Such reliance was based upon the fact that (i) the issuance of the Securities did not involve a public offering, (ii) Orthofix Holdings, Inc. represented that they are accredited investors and (iii) Orthofix Holdings, Inc. made certain investment representations.

On March 29, 2018, the Company issued a press release regarding the financing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

Index to Exhibits

Bone Biologics Corp Exhibit
EX-10.1 2 ex10-1.htm   Exhibit 10.1   SUBSCRIPTION AGREEMENT   Bone Biologics Corporation 2 Burlington Woods Dr.,…
To view the full exhibit click here


Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.

An ad to help with our costs